Global Ulcerative Colitis Market Projected to Reach $9.48 Billion by 2028, Driven by Telemedicine and Innovative Therapies
20 févr. 2024 04h45 HE
|
Research and Markets
Dublin, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The ulcerative colitis market has grown...
Global Inflammatory Bowel Disease Treatment Market Set to Soar with Predicted 5.84% CAGR by 2034
29 janv. 2024 05h04 HE
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Inflammatory Bowel Disease Treatment Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. ...
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
09 janv. 2024 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD),...
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
27 déc. 2023 06h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Artificial Intelligence (AI) in Inflammatory Bowel Disease Market Size, Growth, Demand, Trends, Report By 2032
15 déc. 2023 10h00 HE
|
Precedence Research
Ottawa, Dec. 15, 2023 (GLOBE NEWSWIRE) -- The global artificial intelligence (AI) in inflammatory bowel disease market is expected to expand at a remarkable CAGR during the forecast period 2023 to...
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
06 déc. 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
30 nov. 2023 16h48 HE
|
Biora Therapeutics, Inc.
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
13 nov. 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was incorrect. The corrected release follows: ...
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
09 nov. 2023 07h35 HE
|
ZyVersa Therapeutics
NLRP3 inflammasome inhibition attenuates intestinal inflammation and tissue damage, and significantly improves symptoms in IBD animal model.
Organovo Highlights FXR314 Combination Therapy Potential and Plan
08 nov. 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...